Conversations powered by KPMG Luxembourg

Where pharma and funds converge | Part 2

23 min · 28 feb 2025
aflevering Where pharma and funds converge | Part 2 artwork

Beschrijving

In Part 2 of our podcast episodes on the pharmaceutical and funds industries, Annick Breton (Partner, Head of Consulting, KPMG Luxembourg) and our esteemed guests explore the critical roles that Artificial Intelligence and regulatory decision-makers have in creating a more transparent, trustworthy ecosystem for the two sectors. The key industry players who sat down with Annick were Romain Labbé (Secretary General at the IML), Natasha Deloge (Head of the Innovation Division at the CSSF), Pierre Mottion (Head of DLT and Strategy/Investment Fund Services at Clearstream), and Matthias Van den Eede (Head of Digital Business Development & Beewise at Azimut Investments).

Reacties

0

Wees de eerste die een reactie plaatst

Meld je nu aan en word lid van de Conversations powered by KPMG Luxembourg community!

Probeer gratis

Probeer 14 dagen gratis

€ 9,99 / maand na proefperiode. · Elk moment opzegbaar.

  • Podcasts die je alleen op Podimo hoort
  • 20 uur luisterboeken / maand
  • Gratis podcasts

Alle afleveringen

10 afleveringen

aflevering Where pharma and funds converge | Part 1 artwork

Where pharma and funds converge | Part 1

In Part 1 of this two-episode special of Conversations powered by KPMG Luxembourg, we dive into the converging worlds of the funds industry and pharmaceuticals. Featuring Annick Breton (Partner, Head of Consulting at KPMG Luxembourg), this episode brings together Romain Labbé (Secretary General at the IML), Natasha Deloge (Head of the Innovation Division at the CSSF), Pierre Mottion (Head of DLT and Strategy/Investment Fund Services at Clearstream), and Matthias Van den Eede (Head of Digital Business Development & Beewise at Azimut Investments), as they discuss the common similarities and challenges affecting their industries. Part 1 of this topic delves into the issues surrounding ongoing consumer confidence and how it is affecting the pharmaceutical and investment funds ecosystems.

28 feb 202526 min